The dipeptidyl peptidase‐4 inhibitor PHX1149 improves blood glucose control in patients with type 2 diabetes mellitus

@article{GarciaSoria2008TheDP,
  title={The dipeptidyl peptidase‐4 inhibitor PHX1149 improves blood glucose control in patients with type 2 diabetes mellitus},
  author={G Garcia-Soria and Guillermo Gonz{\'a}lez-G{\'a}lvez and Georges Argoud and M Gerstman and Thomas W. Littlejohn and Sherwyn L. Schwartz and A Marie O'Farrell and X F Li and Julie M. Cherrington and Cathy Bennett and H P Guler},
  journal={Diabetes},
  year={2008},
  volume={10}
}
Aim:  To determine the efficacy and tolerability of PHX1149, a novel dipeptidyl peptidase‐4 (DPP4) inhibitor, in patients with type 2 diabetes. 
Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12‐week, double‐blind, randomized, placebo‐controlled, multicentre trial
Aim: To determine efficacy and tolerability of dutogliptin, a dipeptidyl peptidase 4 (DPP4) inhibitor, in patients with type 2 diabetes mellitus.
DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITION: A NOVEL APPROACH FOR THE TREATMENT OF TYPE II DIABETES MELLITUS
TLDR
The present review will give an insight into the development of several DPP-4 inhibitors and their potential prospects in the treatment of Type II Diabetes Mellitus.
Population pharmacokinetic analysis of dutogliptin, a selective dipeptidyl peptidase‐4 inhibitor
TLDR
Results suggest that a reduction in dosing from 400 to 200 mg daily is warranted in T2DM patients with moderate renal impairment and no dose adjustments were deemed necessary for other evaluated patient characteristics and coadministration with metformin.
New Drugs in Development for the Treatment of Diabetes
TLDR
A variety of new agents are in development for the treatment of type 1 or type 2 diabetes, including unique peroxisome proliferator-activated receptor agonists, selective sodium glucose cotransporter 2 inhibitors, and several other unique agents now in development.
Incretin-based therapies for type 2 diabetes mellitus
TLDR
This Review highlights the current understanding of the mechanisms of action of incretin-based drugs, with an emphasis on the emerging clinical profile of new agents.
Cardiovascular Safety of Dipeptidyl-Peptidase IV Inhibitors: A Meta-Analysis of Placebo-Controlled Randomized Trials
TLDR
In patients with type 2 diabetes, the safety profile of DPP-4 inhibitors is similar to placebo, and there is only weak evidence for an increased risk of heart failure.
Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy
  • B. Gallwitz
  • Medicine, Biology
    Expert opinion on investigational drugs
  • 2011
TLDR
The reader will gain detailed pharmacological and clinical information on alogliptin, dutogli leptin and linagliptin and will learn how these DPP IV inhibitors may widen the whole drug class.
Hormony inkretynowe w leczeniu cukrzycy typu 2. Część II. Inkretyny — nowe możliwości farmakoterapii cukrzycy typu 2 Incretin hormones in the treatment of type 2 diabetes. Part II. Incretins — new possibilities for pharmacotherapy of type 2 diabetes
TLDR
Multidirectional, glucoregulative mechanism of action of these drugs, aiming at the pathogenesis of the disease, restores the proper function of the intestinal-pancreatic axis in subjects with type 2 diabetes and ensures good metabolic control and improvement in quality of life in this group of patients.
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
TLDR
There is no evidence from prospective comparative trials or from observational cohort studies that metformin is associated with an increased risk of lactic acidosis, or with increased levels of lactate, compared to other anti-hyperglycemic treatments.
...
1
2
3
...

References

SHOWING 1-10 OF 23 REFERENCES
DPP‐4 inhibitors and their potential role in the management of type 2 diabetes
  • A. Barnett
  • Medicine, Biology
    International journal of clinical practice
  • 2006
TLDR
The leading DPP‐4 inhibitors have shown clinically significant HbA1c reductions up to 1 year of treatment and offer many potential advantages over existing diabetes therapies including a low risk of hypoglycaemia, no effect on body weight, and the potential for the regeneration and differentiation of pancreatic β‐cells.
Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes.
TLDR
Vildagliptin is an incretin degradation inhibitor that improves beta-cell function in diabetic patients by increasing the insulin secretory tone.
Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
TLDR
In patients with type 2 diabetes, near maximal glucose-lowering efficacy of sitagliptin after single oral doses was associated with inhibition of plasma DPP-4 activity of 80% or greater, corresponding to a plasma sitgliptin concentration of 100 nm or greater and an augmentation of active GLP-1 and GIP levels of 2-fold or higher after an OGTT.
Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes.
TLDR
Improved metabolic control by DPP-4 inhibition in type 2 diabetes is seen in association with reduced glucagon levels and, despite the lower glycemia, unaltered insulin levels.
Pharmacodynamics of Vildagliptin in Patients With Type 2 Diabetes During OGTT
TLDR
Unlike findings during mixed‐meal challenges, vildagliptin increases plasma insulin levels during oral glucose tolerance tests in patients with type 2 diabetes mellitus.
Alpha cell function in health and disease: influence of glucagon-like peptide-1
TLDR
Therapeutic approaches based around GLP-1 have the potential to improve both alpha cell and beta cell function, and could be of benefit in patients with a broad range of metabolic disorders.
Loss of dipeptidylpeptidase IV activity in chronic rhinosinusitis contributes to the neurogenic inflammation induced by substance P in the nasal mucosa
  • E. Grouzmann, M. Monod, J. Lacroix
  • Medicine, Biology
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  • 2002
TLDR
A new pathophysiological pathway for rhinitis is suggested based on clinical observations in humans, indicating the involvement of an enzyme to modulate non‐adrenergic and non‐cholinergicnon‐ cholinergic substrate that occurred during nasal dysfunctions.
...
1
2
3
...